Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 17-year-old is considering starting finasteride and minoxidil for hair loss, despite concerns about potential side effects and the impact on development. The user is advised to check if puberty is complete and to consider using only minoxidil until adulthood.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The conversation discusses using RU58841 or Pyrilutamide for hair loss, with some users suggesting switching to more proven treatments like oral or topical finasteride. One user reports no progress with RU58841, finasteride, and minoxidil, and mentions experiencing regression.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

A 15-year-old is upset about androgenic alopecia and its effect on self-esteem. Recommendations include minoxidil, microneedling, hair systems, and focusing on self-confidence and therapy.

The conversation discusses using stemoxydine as a carrier for RU58841 and the search for affordable, premixed PG+E. Minoxidil is considered as an alternative, but simplicity is preferred.

Verteporfin, combined with microneedling, shows promise for hair regrowth by allowing hair follicles to grow in wounds, but it's expensive and painful. Pai-1 inhibitors may also help prevent hair loss by degrading fibrosis, and some users continue using minoxidil alongside these treatments.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

A 23-year-old is experiencing hair loss and is using a regimen including topical Minoxidil, finasteride, spironolactone, and Estradiol gel as part of hormone replacement therapy (HRT). They are hopeful for hair regrowth and are considering using a micro needler, with others suggesting that their current treatment could lead to significant improvement.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

A 19-year-old started Dutasteride at 17 to combat aggressive hair thinning, which halted his facial hair development despite having strong beard genetics. He also used oral and topical Minoxidil without success for facial hair, and the discussion highlights the impact of DHT blockers on beard growth.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user reported significant hair improvement using oral minoxidil, Rogaine 5%, and spironolactone but experienced worsening PMS. They seek advice on managing the PMS symptoms.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

The user is experiencing hair loss despite using estradiol, bicalutamide, dutasteride, and topical minoxidil. They stopped minoxidil temporarily, which worsened their condition, and are considering oral minoxidil but are concerned about side effects and cost.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.

A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

A 22-year-old is experiencing hair loss after transitioning from fem HRT to DIY testosterone therapy and is considering using Dutasteride while also taking Saw Palmetto. They are concerned about the impact on virilization and proper development.

A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.